详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways

74| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [a]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China [b]Simcere Pharmaceutical Co., Ltd, Nanjing, 210018, China [c]The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, 210018, China [d]The First People's Hospital of Yunnan Province, Kunming, 650032, China

出处：

DOI：

ISSN：

关键词： EGFR-TKI resistance IRS4 NSCLC PI3K/Akt Ras-MAPK

摘要：

IRS4 is a member of the insulin receptor substrate (IRS) protein family. It acts as a cytoplasmic adaptor protein, integrating and transmitting signals from receptor protein tyrosine kinases to the intracellular environment. IRS4 can induce mammary tumorigenesis and is usually overexpressed in non-small cell lung cancer (NSCLC). However, little is known about the role of IRS4 in the development and progression of lung cancer. In this study, we show that IRS4 knockout suppresses the proliferation, colony formation, migration, and invasion of A549 lung cancer cells, as well as tumor growth in a nude mouse xenograft model. In contrast, stable expression of IRS4 showed the opposite effects. As expected, IRS4 was found to activate the PI3K/Akt and Ras-MAPK pathways, and we also showed that IRS4 depletion significantly enhanced the sensitivity of EGFR tyrosine kinase inhibitor (EGFR-TKI)-resistant cells to gefitinib. Taken together, these results show that IRS4 promotes NSCLC progression and may represent a potential therapeutic target for EGFR-TKI-resistant NSCLC. © 2021 Elsevier Inc.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区肿瘤学 4 区细胞生物学

最新[2023]版：

大类 | 3 区生物学

小类 | 4 区细胞生物学 4 区肿瘤学

JCR分区：

出版当年[2020]版：

Q3 CELL BIOLOGY Q3 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY Q3 CELL BIOLOGY

影响因子： 3.3 最新[2023版] 3.3 最新五年平均 3.905 出版当年[2020版] 4.121 出版当年五年平均 3.383 出版前一年[2019版] 4.145 出版后一年[2021版]

第一作者：

第一作者机构： [a]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China

共同第一作者：

通讯作者：

通讯机构： [a]Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China [*1]Faculty of Life Science and Technology, Kunming University of Science and Technology, No.727 South Jingming Road, Kunming, Yunnan Province, 650500, China [*2]Faculty of Life Science and Technology, Kunming University of Science and Technology, No.727 South Jingming Road, Kunming, Yunnan Province, 650500, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]芬太尼通过PI3K/Akt信号通路调控宫颈癌细胞增殖迁移 [2]芬太尼通过PI3 K/Akt信号通路调控宫颈癌细胞增殖迁移 [3]VEGF介导PI3K-AKT信号通路在BMSCs移植治疗大鼠脊髓缺血再灌注损伤中的作用 [4]Silencing circPVT1 enhances radiosensitivity in non-small cell lung cancer by sponging microRNA-1208. [5]PI3K/AKT/p-AKT在宫颈癌组织中的表达及其与Ki67关系的研究 [6]Acupuncture Improves Endometrial Angiogenesis by Activating PI3K/AKT Pathway in a Rat Model with PCOS [7]Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway [8]MiR-126 inhibits vascular endothelial cell apoptosis through targeting PI3K/Akt signaling [9]Belamcanda chinensis extract inhibits non-small cell lung cancer proliferation and induces apoptosis via inhibiting the MAPK (Ras/ Raf) and Akt pathways [10]TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway